First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC
Status:
COMPLETED
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
In this clinical study, investigators explore the efficacy and safety of a combination therapy regimen with antiangiogenic agent (apatinib), ICI (tislelizumab), and chemotherapy (capecitabine+ Oxaliplatin, XELOX) as first-line treatment for HER2-negative, advanced G/GEJ cancer patients with signet ring cell carcinoma or peritoneal metastasis.